Latest Product Updates and Feature Enhancements on Indegene iON
Indegene launches NEXT medical writing automation platform with GenAI
Indegene has launched NEXT Medical Writing Automation, a platform that uses generative AI to enhance medical writing. This tool integrates with existing systems to produce compliant documents efficie...ntly, allowing medical writers to focus on strategic tasks. It aims to streamline operations in clinical development and regulatory submissions by leveraging Indegene's AI engine, Cortex.
Strategic Partnerships and Integrations of Indegene iON
Indegene Selects Verified Market Research to Gain Strategic Insight into the Conjunctivitis Allergy Market
Indegene partnered with Verified Market Research to obtain strategic insights into the conjunctivitis allergy market. This collaboration aimed to support Indegene's advisory role for a client by prov...iding detailed market sizing, segmentation, and competitive analysis. The insights helped shape the client's portfolio expansion strategy, demonstrating Indegene's commitment to delivering precise and actionable data.
Indegene announces strategic partnership with Datavant
Indegene and Datavant have formed a strategic partnership to enhance patient recruitment for clinical trials, focusing on rare diseases. By integrating Datavant's data enrichment capabilities with In...degene's NEXT Patient Recruitment platform, the collaboration aims to streamline trial enrollment, reduce screen failures, and improve recruitment efficiency for biopharmaceutical companies.
Mergers, Acquisitions, and Business Moves by Indegene iON
Indegene acquires Pennsylvania-based BioPharm
Indegene has acquired BioPharm, a specialized marketing services agency based in Pennsylvania, to enhance its commercialization portfolio with AdTech capabilities. This acquisition, executed through ...Indegene's subsidiary ILSL Inc., aims to integrate AI and digital advertising to offer precise, scalable solutions for pharma companies. BioPharm's expertise in omnichannel strategy and data-driven campaign execution strengthens Indegene's leadership in the data-driven omnichannel and media space.
Funding News and Financial Performance of Indegene iON
Indegene Q3 results: Revenue surges 31% to 942 crore but profit, margins dip
Indegene's Q3 FY26 results show a 30.8% revenue increase to 942 crore, marking its first $100 million-plus revenue quarter. Despite this, net profit fell 6.2% to 102.9 crore, and operating margins na...rrowed to 17%. Key achievements include three customers surpassing $25 million in annual revenue. Recent acquisitions of BioPharm and Warn & Co aim to enhance domain expertise.
Indegene Board to Approve Q3 2026 Financial Results
Indegene's Board of Directors will meet on January 29, 2026, to review and approve the unaudited financial results for Q3 2026. The meeting will also address share allotment under the RSU Scheme 2020.... The trading window for company securities is closed until 48 hours after the results are declared.
Corporate News and Organizational Updates on Indegene iON
Indegene expands its consulting practice to support life sciences organizations
Indegene has expanded its consulting practice to assist life sciences organizations in managing large-scale transformations. The company has appointed Gobin Chandra as the head of its Integrated Cons...ulting Practice. This expansion includes acquiring UK-based WARN & Co. to enhance its transformation consulting capabilities.
